NBSE insider filings
NeuBase Therapeutics, Inc. — 44 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-09-18. Screen NBSE transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for NBSE between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — NeuBase Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-09-18 | 4 | Symetryx Corp — 10% owner | Sale (S): 129,108 @ $1.44 · Sale (S): 103,337 @ $1.26 · Sale (S): 50,000 @ $1.19 | EDGAR |
| 2023-09-11 | 4 | Symetryx Corp — 10% owner | Sale (S): 74,852 @ $1.80 · Sale (S): 128,847 @ $1.53 · Sale (S): 3,376 @ $1.44 | EDGAR |
| 2023-09-07 | 4 | Symetryx Corp — 10% owner | Purchase (P): 61,076 @ $0.98 | EDGAR |
| 2023-08-04 | 4 | Stephan Dietrich A — Founder and CEO, Director, 10% owner | Option exercise (M): 93,234 @ $0.02 · Option exercise (M): 93,234 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Branning Todd P. — Chief Financial Officer | Grant/award (A): 54,200 @ $0 | EDGAR |
| 2023-03-17 | 4 | Stephan Dietrich A — CEO and Director, Director, 10% owner | Grant/award (A): 153,000 @ $0 | EDGAR |
| 2023-02-15 | 4 | Stephan Dietrich A — President and CEO, Director, 10% owner | Option exercise (M): 655,000 @ $0 · Option exercise (M): 655,000 (derivative) @ $0 | EDGAR |
| 2022-11-04 | 4 | Branning Todd P. — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2022-09-30 | 4 | Stephan Dietrich A — CEO, Director, 10% owner | Option exercise (M): 750,000 @ $0.00 · Option exercise (M): 750,000 (derivative) @ $0.00 | EDGAR |
| 2022-09-12 | 4 | RICHMAN ERIC I — Director | Grant/award (A): 37,600 (derivative) @ $0 | EDGAR |
| 2022-09-12 | 4 | PRENDERGAST FRANKLYN G — Director | Grant/award (A): 37,600 (derivative) @ $0 | EDGAR |
| 2022-09-12 | 4 | McDougall Gerald J — Director | Grant/award (A): 37,600 (derivative) @ $0 | EDGAR |
| 2022-09-12 | 4 | Ende Eric J — Director | Grant/award (A): 37,600 (derivative) @ $0 | EDGAR |
| 2022-09-12 | 4 | GOLDSTEIN DOV A MD — Director | Grant/award (A): 37,600 (derivative) @ $0 | EDGAR |
| 2022-04-01 | 4 | Mann William Roland — Chief Operating Officer | Purchase (P): 6,200 @ $1.92 | EDGAR |
| 2022-03-21 | 4 | Branning Todd P. — Chief Financial Officer | Purchase (P): 10,000 @ $1.81 | EDGAR |
| 2022-03-18 | 4 | Branning Todd P. — Chief Financial Officer | Purchase (P): 10,000 @ $1.62 · Purchase (P): 10,000 @ $1.74 | EDGAR |
| 2022-03-07 | 4 | RICHMAN ERIC I — Director | Purchase (P): 1,580 @ $1.58 · Purchase (P): 1,300 @ $1.72 · Purchase (P): 1,000 @ $1.62 | EDGAR |
| 2022-01-25 | 4 | Mann William Roland — Chief Operating Officer | Grant/award (A): 60,180 (derivative) @ $0 | EDGAR |
| 2022-01-25 | 4 | Rojas-Caro Sandra — Chief Medical Officer | Grant/award (A): 44,592 (derivative) @ $0 | EDGAR |
| 2022-01-25 | 4 | Stephan Dietrich A — President and CEO, Director, 10% owner | Grant/award (A): 306,000 (derivative) @ $0 | EDGAR |
| 2022-01-10 | 4 | Branning Todd P. — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Stephan Dietrich A — President and CEO, Director, 10% owner | Option exercise (M): 42,250 @ $0.00 · Option exercise (M): 42,250 (derivative) @ $0.00 | EDGAR |
| 2022-01-05 | 4 | Ende Eric J — Director | Grant/award (A): 165,803 (derivative) @ $0 | EDGAR |
| 2021-09-24 | 4 | Mann William Roland — COO | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-09-17 | 4 | McDougall Gerald J — Director | Grant/award (A): 38,135 (derivative) @ $0 | EDGAR |
| 2021-09-17 | 4 | PRENDERGAST FRANKLYN G — Director | Grant/award (A): 38,135 (derivative) @ $0 | EDGAR |
| 2021-09-17 | 4 | RICHMAN ERIC I — Director | Grant/award (A): 38,135 (derivative) @ $0 | EDGAR |
| 2021-09-17 | 4 | GOLDSTEIN DOV A MD — Director | Grant/award (A): 38,135 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | GOLDSTEIN DOV A MD — Director | Purchase (P): 8,000 @ $4.75 | EDGAR |
| 2021-05-25 | 4 | Rojas-Caro Sandra — Chief Medical Officer | Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2021-05-25 | 4 | Motesharei Kianoush — See Remarks | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | McDougall Gerald J — Director | Grant/award (A): 92,219 (derivative) @ $0 | EDGAR |
| 2021-04-27 | 4 | RICHMAN ERIC I — Director | Purchase (P): 5,000 @ $5 | EDGAR |
| 2021-04-27 | 4 | Stephan Dietrich A — President and CEO, Director, 10% owner | Purchase (P): 12,000 @ $5 | EDGAR |
| 2021-04-27 | 4 | Mann William Roland — COO | Purchase (P): 5,000 @ $5 | EDGAR |
| 2021-04-27 | 4 | GOLDSTEIN DOV A MD — Director | Purchase (P): 12,000 @ $5 | EDGAR |
| 2020-12-30 | 4 | Stephan Dietrich A — President and CEO, Director, 10% owner | Gift (G): 2,547,639 @ $0 · Gift (G): 1,273,819 @ $0 · Gift (G): 1,273,819 @ $0 · Gift (G): 1,273,820 @ $0 · Grant/award (A): 164,925 (derivative) @ $0 | EDGAR |
| 2020-12-30 | 4 | Backenroth Samuel — CFO, Treasurer & Secretary | Grant/award (A): 41,915 (derivative) @ $0 | EDGAR |
| 2020-12-02 | 4 | Bradshaw Curt — Chief Scientific Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | Miralles Gines Diego — Director | Grant/award (A): 14,634 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | RICHMAN ERIC I — Director | Grant/award (A): 14,634 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | PRENDERGAST FRANKLYN G — Director | Grant/award (A): 14,634 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | GOLDSTEIN DOV A MD — Director | Grant/award (A): 14,634 (derivative) @ $0 | EDGAR |
Recent 8-K events — NeuBase Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-01-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-27 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-13 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-03 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-05 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NBSE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs